Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cardiology
Jacc Intervention Publishes Mivs Vestasync I Trial Preliminary Results
November 8th, 2008
MIV Therapeutics, Inc. (OTC/BB: MIVI) (Frankfurt: MIV), a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, announced that the Journal of the American College of Cardiology Intervention (JACC Intervention) published preliminary results from the VESTASYNC I trial. The peer-reviewed article entitled "Preliminary Results of the Hydroxyapatite Non-Polymer-Based Sirolimus-Eluting Stent for the Treatment of Single De Novo Coronary Lesions - A First-In-Human Analysis of a Third Generation Drug-Eluting Stent (DES) System" appears in the October 21st edition of JACC and is available online at...
Source: Law & Health Weekly (2008-11-08)
|
